JCA Pulse › JCA discontinued
JCA discontinuedAutologous TIL (Tacquell): EU joint clinical assessment
Melanoma (autologous melanoma-derived tumour-infiltrating lymphocytes)
This assessment was discontinued.
Overview
- Company
- Netherlands Cancer Institute
- Therapy area
- Solid tumours · Skin
- Indication
- Melanoma (autologous melanoma-derived tumour-infiltrating lymphocytes)
- EMA validation
- 27 Mar 2025
- Discontinued
- 22 Jun 2026
- JCA assessor
- HAS, France
- Co-assessor
- AOTMiT, Poland
- Regulatory status
- EU marketing authorisation refused 14 Sep 2026.
- Reason
- The JCA dossier did not meet the requirements of Article 9(2)–(4) of the HTA Regulation.
Next milestones
- 14 Sep 2026EU marketing authorisation refused · EU · source
Sources
Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.
From Evidaxia
- EU JCA dossiers and PICO scopingSupport from PICO scoping to the dossier
- JCA PICO scoping: process and preparationHow assessors set the scope
- EU JCA timelineEvery upcoming milestone
Also in Solid tumours
- Bifikafusp alfa / onfekafusp alfa (Nidlegy)Melanoma, neoadjuvant
- CamizestrantHR+/HER2− breast cancer, ESR1 switch
- CosibelimabCutaneous squamous cell carcinoma
- DaraxonrasibMetastatic pancreatic cancer
- Ensartinib (Gevalka)ALK-positive NSCLC
- FuzuloparibmCRPC, first line